Gallacher, Daniel
Armoiry, Xavier
Auguste, Peter
Court, Rachel
Mantopoulos, Theodoros
Patterson, Jacoby
De Santis, Maria
Cresswell, Joanne
Mistry, Hema
Funding for this research was provided by:
Health Technology Assessment Programme (16/108/19)
Article History
First Online: 21 July 2018
Compliance with Ethical Standards
:
: This project was funded by the NIHR HTA programme (project number 16/108/19). See the HTA programme website (ExternalRef removed) for further project information.
: DG, XA, PA, RC, TM, JP, JC and HM have no other conflicts of interest that are directly relevant to the content of this article. MDS has received consulting fees/honoraria from Amgen, Astellas Pharma, AstraZeneca, Bayer AG, Bristol-Myers Squibb, Celgene, Dendreon, Eisai, ESSA Pharma, Ferring Pharmaceuticals, GlaxoSmithKline, Incyte, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Pierre Fabre Group, Roche, Sanofi, Seattle Genetics, Shionogi, Synthon, Takeda and Teva/Oncogenex.